About Albany Molecular Research (NASDAQ:AMRI)
Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:AMRI
CUSIPN/A
Phone+1-518-4640279
Debt
Debt-to-Equity Ratio0.62%
Current Ratio0.68%
Quick Ratio0.37%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5.93%
Return on Equity-13.39%
Return on Assets-3.42%
Miscellaneous
Employees3,085
Outstanding Shares43,120,000
Albany Molecular Research (NASDAQ:AMRI) Frequently Asked Questions
What is Albany Molecular Research's stock symbol?
Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."
How were Albany Molecular Research's earnings last quarter?
Albany Molecular Research, Inc. (NASDAQ:AMRI) posted its earnings results on Tuesday, May, 10th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.21 by $0.14. The biotechnology company earned $102.80 million during the quarter, compared to the consensus estimate of $107.20 million. Albany Molecular Research had a negative return on equity of 13.39% and a negative net margin of 5.93%. View Albany Molecular Research's Earnings History.
What price target have analysts set for AMRI?
4 equities research analysts have issued 1 year price targets for Albany Molecular Research's shares. Their predictions range from $18.00 to $18.00. On average, they anticipate Albany Molecular Research's share price to reach $18.00 in the next year. View Analyst Ratings for Albany Molecular Research.
Who are some of Albany Molecular Research's key competitors?
Some companies that are related to Albany Molecular Research include Retail Opportunity Investments (ROIC), Denali Therapeutics (DNLI), CyberArk (CYBR), Redfin (RDFN), Varonis Systems (VRNS), Auxilium Pharmaceuticals (AUXL), Hostess Brands (TWNK), Homeinns Hotel Group (HMIN), Aimmune Therapeutics (AIMT), WD-40 (WDFC), Innospec (IOSP), Banner (BANR), Brooks Automation (BRKS), Criteo (CRTO), International Speedway (ISCA), TiVo (TIVO), Pinnacle Entertainment (PNK) and Insmed (INSM).
Who are Albany Molecular Research's key executives?
Albany Molecular Research's management team includes the folowing people:
- William S. Marth, President, Chief Executive Officer, Director
- Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
- Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
- Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
- , Bio & Compensation -
- Milton Boyer, Senior Vice President - Drug Product Manufacturing
- , Bio & Compensation -
- Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
- George Svokos, Chief Commercial Officer and Senior Vice President, API
- Jimmy Wang Ph.D., Chief Information Officer
- , Bio & Compensation -
- Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
- David H. Deming, Director
Has Albany Molecular Research been receiving favorable news coverage?
Headlines about AMRI stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Albany Molecular Research earned a daily sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Albany Molecular Research?
Shares of AMRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albany Molecular Research's stock price today?
One share of AMRI stock can currently be purchased for approximately $21.74.
How big of a company is Albany Molecular Research?
Albany Molecular Research has a market capitalization of $937.41 million. Albany Molecular Research employs 3,085 workers across the globe.
How can I contact Albany Molecular Research?
Albany Molecular Research's mailing address is 21 Corporate Cir, PO Box 15098, ALBANY, NY 12203-5154, United States. The biotechnology company can be reached via phone at +1-518-4640279.
MarketBeat Community Rating for Albany Molecular Research (AMRI)
MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe AMRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Albany Molecular Research (NASDAQ:AMRI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Albany Molecular Research in the last 12 months. Their average twelve-month price target is $18.00, suggesting that the stock has a possible downside of 17.20%. The high price target for AMRI is $18.00 and the low price target for AMRI is $18.00. There are currently 4 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $18.00 | $18.00 | $18.00 | $18.00 |
| Price Target Upside: | 17.20% downside | 17.09% downside | 17.09% downside | 17.09% downside |
Albany Molecular Research (NASDAQ:AMRI) Consensus Price Target History
Albany Molecular Research (NASDAQ:AMRI) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Albany Molecular Research (NASDAQ:AMRI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Albany Molecular Research (NASDAQ AMRI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 72.10%
Albany Molecular Research (NASDAQ AMRI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/2/2016 | Anthony J Maddaluna | Director | Buy | 1,518 | $16.46 | $24,986.28 | 7,408 |  |
| 11/30/2016 | Steven R Hagen | SVP | Sell | 9,000 | $16.71 | $150,390.00 | 43,913 | |
| 11/16/2016 | Lori M Henderson | SVP | Sell | 6,000 | $17.00 | $102,000.00 | 51,337 | |
| 11/10/2016 | Steven R Hagen | SVP | Sell | 785 | $16.79 | $13,180.15 | 34,913 | |
| 8/9/2016 | Steven R Hagen | SVP | Sell | 1,401 | $15.29 | $21,421.29 | 36,163 | |
| 5/31/2016 | Kevin Oconnor | Director | Sell | 5,000 | $14.41 | $72,050.00 | 52,955 | |
| 5/16/2016 | William S Marth | CEO | Buy | 12,500 | $12.86 | $160,750.00 | 524,143 | |
| 5/13/2016 | George Svokos | COO | Buy | 12,500 | $12.82 | $160,250.00 | 108,685 | |
| 5/13/2016 | Steven R Hagen | SVP | Sell | 2,361 | $12.77 | $30,149.97 | 37,564 | |
| 11/9/2015 | Ambra Constance M D | Major Shareholder | Sell | 50,000 | $19.60 | $980,000.00 | 2,365,818 | |
| 8/17/2015 | Steven R Hagen | SVP | Sell | 1,000 | $20.45 | $20,450.00 | | |
| 6/10/2015 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $19.77 | $395,400.00 | | |
| 6/8/2015 | Steven R Hagen | SVP | Sell | 5,000 | $19.99 | $99,950.00 | | |
| 6/4/2015 | William S Marth | CEO | Buy | 10,000 | $19.98 | $199,800.00 | | |
| 6/1/2015 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $19.69 | $590,700.00 | | |
| 5/11/2015 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $19.11 | $382,200.00 | | |
| 5/8/2015 | Steven R Hagen | SVP | Sell | 14,500 | $19.27 | $279,415.00 | | |
| 4/10/2015 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $18.50 | $370,000.00 | | |
| 3/17/2015 | Steven R Hagen | SVP | Sell | 3,500 | $18.53 | $64,855.00 | | |
| 3/12/2015 | Kevin Oconnor | Director | Sell | 5,000 | $18.22 | $91,100.00 | | |
| 3/10/2015 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $17.65 | $353,000.00 | | |
| 3/10/2015 | George Svokos | Insider | Buy | 10,000 | $17.72 | $177,200.00 | | |
| 3/5/2015 | William S Marth | CEO | Buy | 20,000 | $17.70 | $354,000.00 | | |
| 3/2/2015 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $16.39 | $491,700.00 | | |
| 2/10/2015 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $16.91 | $338,200.00 | | |
| 2/2/2015 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $16.32 | $489,600.00 | | |
| 1/12/2015 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $16.45 | $329,000.00 | | |
| 1/7/2015 | Stuart M Cable | Major Shareholder | Sell | 7,694 | $16.00 | $123,104.00 | | |
| 1/5/2015 | Stuart M Cable | Major Shareholder | Sell | 22,306 | $16.21 | $361,580.26 | | |
| 12/10/2014 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $16.24 | $324,800.00 | | |
| 12/5/2014 | Stuart M Cable | Major Shareholder | Sell | 13,307 | $16.00 | $212,912.00 | | |
| 12/4/2014 | Stuart M Cable | Major Shareholder | Sell | 16,693 | $16.00 | $267,088.00 | | |
| 11/10/2014 | William S Marth | CEO | Buy | 30,000 | $17.01 | $510,300.00 | | |
| 10/10/2014 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $21.62 | $432,400.00 | | |
| 10/1/2014 | Lori M Henderson | SVP | Sell | 1,000 | $21.48 | $21,480.00 | | |
| 10/1/2014 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $21.61 | $648,300.00 | | |
| 9/10/2014 | Ambra Constance M D | Major Shareholder | Sell | 20,000 | $20.12 | $402,400.00 | | |
| 9/2/2014 | Lori M Henderson | SVP | Sell | 2,500 | $19.56 | $48,900.00 | | |
| 8/28/2014 | Steven R Hagen | SVP | Sell | 1,250 | $19.74 | $24,675.00 | | |
| 8/14/2014 | Michael M Nolan | CFO | Sell | 10,000 | $19.76 | $197,600.00 | | |
| 8/12/2014 | Lori M Henderson | SVP | Sell | 30,000 | $19.05 | $571,500.00 | | |
| 8/11/2014 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $18.99 | $379,800.00 | | |
| 8/8/2014 | Steven R Hagen | SVP | Sell | 10,797 | $18.99 | $205,035.03 | | |
| 8/1/2014 | Lori M Henderson | SVP | Sell | 2,500 | $18.56 | $46,400.00 | | |
| 8/1/2014 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $18.69 | $560,700.00 | | |
| 7/10/2014 | Ambra Thomas E Phd D | Director | Sell | 20,000 | $20.94 | $418,800.00 | | |
| 7/1/2014 | Lori M Henderson | SVP | Sell | 2,500 | $20.62 | $51,550.00 | | |
| 7/1/2014 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $21.00 | $630,000.00 | | |
| 6/3/2014 | Steven R Hagen | SVP | Sell | 2,500 | $16.93 | $42,325.00 | | |
| 5/16/2014 | Steven Hagen | SVP | Sell | 1,250 | $15.45 | $19,312.50 | 33,433 | |
| 5/15/2014 | George Svokos | SVP | Buy | 10,000 | $15.60 | $156,000.00 | 54,584 | |
| 5/12/2014 | Steven Hagen | SVP | Sell | 5,897 | $15.00 | $88,455.00 | 33,433 | |
| 5/12/2014 | William Marth | CEO | Buy | 30,000 | $15.40 | $462,000.00 | 313,699 | |
| 5/1/2014 | Lori Henderson | VP | Sell | 2,500 | $15.73 | $39,325.00 | 53,997 | |
| 5/1/2014 | Stuart Cable | major shareholder | Sell | 30,000 | $15.98 | $479,400.00 | | |
| 4/1/2014 | Lori Henderson | VP | Sell | 2,500 | $18.74 | $46,850.00 | 56,497 | |
| 4/1/2014 | Stuart Cable | major shareholder | Sell | 30,000 | $18.52 | $555,600.00 | | |
| 2/27/2014 | Arthur Roth | Director | Sell | 5,000 | $15.95 | $79,750.00 | 36,856 | |
| 2/27/2014 | Steven Hagen | SVP | Sell | 3,000 | $15.73 | $47,190.00 | 34,838 | |
| 2/25/2014 | Steven Hagen | SVP | Sell | 2,500 | $15.19 | $37,975.00 | 34,838 | |
| 2/24/2014 | Michael Nolan | CFO | Sell | 15,000 | $15.00 | $225,000.00 | 76,093 | |
| 2/21/2014 | Steven Hagen | SVP | Sell | 1,500 | $14.87 | $22,305.00 | 34,838 | |
| 2/19/2014 | Steven Hagen | SVP | Sell | 1,500 | $13.37 | $20,055.00 | 36,338 | |
| 2/13/2014 | Stuart Cable | major shareholder | Sell | 30,000 | $12.00 | $360,000.00 | | |
| 12/4/2013 | Steven Hagen | SVP | Sell | 2,500 | $10.93 | $27,325.00 | 27,414 | |
| 12/3/2013 | William Marth | Director | Buy | 30,000 | $10.75 | $322,500.00 | 91,159 | |
| 11/22/2013 | Steven Hagen | SVP | Sell | 2,300 | $11.55 | $26,565.00 | 27,414 | |
| 11/22/2013 | William Marth | Director | Buy | 20,000 | $11.57 | $231,400.00 | 61,159 | |
| 9/13/2013 | Stuart Cable | major shareholder | Sell | 30,000 | $12.00 | $360,000.00 | | |
| 8/1/2013 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $12.53 | $375,900.00 | | |
| 7/1/2013 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $12.47 | $374,100.00 | | |
| 6/12/2013 | Stuart M Cable | Major Shareholder | Sell | 30,000 | $12.00 | $360,000.00 | | |
| 5/22/2013 | Bruce J Sargent | SVP | Sell | 7,500 | $10.97 | $82,275.00 | | |
| 5/10/2013 | Steven R Hagen | SVP | Sell | 1,200 | $10.40 | $12,480.00 | | |
| 12/3/2012 | William S Marth | Director | Buy | 10,000 | $5.00 | $50,000.00 | | |
| 11/15/2012 | Ambra Thomas E Phd D | CEO | Buy | 10,000 | $3.80 | $38,000.00 | | |
| 8/9/2012 | Steven R Hagen | VP | Sell | 3,000 | $3.00 | $9,000.00 | | |
(Data available from 1/1/2013 forward)
Albany Molecular Research (NASDAQ AMRI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Albany Molecular Research (AMRI) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 17 at 4:17 PM |
| Head-To-Head Contrast: Covance (CVD) versus Albany Molecular Research (AMRI)
www.americanbankingnews.com - March 26 at 1:09 PM |
| Anacor Pharmaceuticals (ANAC) vs. Albany Molecular Research (AMRI) Critical Comparison
www.americanbankingnews.com - March 20 at 5:14 PM |
| Sorrento Tech (ROKA) versus Albany Molecular Research (AMRI) Head to Head Survey
www.americanbankingnews.com - March 10 at 1:37 PM |
| Head-To-Head Survey: Sorrento Tech (ROKA) vs. Albany Molecular Research (AMRI)
www.americanbankingnews.com - March 10 at 1:36 PM |
 | Global Drug Discovery Informatics Market Expected to Reach a Value of US$ 7.8 Bn by 2025 - Outsourced Informatics to Fuel Market Growth
finance.yahoo.com - March 9 at 10:04 AM |
 | NM's second-largest manufacturer showcases new production line
www.bizjournals.com - February 24 at 4:40 PM |
 | Bruker finance chief bids adieu
seekingalpha.com - February 21 at 9:37 AM |
| Albany Molecular Research (AMRI) & Ionis Pharmaceuticals (IONS) Head-To-Head Survey
www.americanbankingnews.com - January 15 at 1:10 AM |
| Albany Molecular Research (AMRI) & Enanta Pharmaceuticals (ENTA) Head-To-Head Contrast
www.americanbankingnews.com - December 18 at 1:46 PM |
| The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022
www.bizjournals.com - November 7 at 5:36 PM |
| The drug discovery services market was valued at USD 8.32 billion in 2017 and expected to grow at a CAGR of 11.6% to reach USD 14.40 billion in 2022
www.bizjournals.com - November 7 at 5:36 PM |
 | Cohen Lawrence B Buys TJX Inc, United Technologies Corp, US Bancorp, Sells Ford Motor Co, ...
www.nasdaq.com - November 4 at 10:23 PM |
| Albany Molecular Research (AMRI) versus OncoMed Pharmaceuticals (OMED) Critical Review
www.americanbankingnews.com - November 1 at 11:12 PM |
 | Drug Discovery Services Market Worth 14.40 Billion USD by 2022
www.marketwatch.com - October 27 at 11:02 PM |
| Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Albany Molecular Research, Inc.
finance.yahoo.com - October 25 at 4:55 PM |
| Albany Molecular Research (AMRI) & Its Competitors Financial Review
www.americanbankingnews.com - October 23 at 6:28 PM |
| AMRI says it's still committed to Buffalo project after private equity takeover
www.bizjournals.com - October 21 at 3:39 PM |
| Albany Molecular Research (AMRI) & Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - October 17 at 8:26 AM |
| Brown Trout Management, LLC Buys IXYS Corp, First South Bancorp, Paragon Commercial Corp, Sells ...
www.nasdaq.com - October 12 at 4:38 PM |
| Head to Head Review: Albany Molecular Research (AMRI) versus Its Rivals
www.americanbankingnews.com - October 1 at 12:18 PM |
| Albany Molecular Research (AMRI) vs. Corvus Pharmaceuticals (CRVS) Head to Head Analysis
www.americanbankingnews.com - September 20 at 4:28 AM |
| Albany Business Review announces 2017 Achievers
www.bizjournals.com - September 14 at 3:05 AM |
| 3ST Research Files Litigation Alleging Fraud and Conversion of Inventor's Intellectual Property Rights by Albany Molecular Research Inc. (AMRI)
finance.yahoo.com - September 12 at 4:05 PM |
| Albany Molecular Research, Inc. (AMRI) Expected to Post Quarterly Sales of $171.94 Million
www.americanbankingnews.com - September 1 at 3:06 AM |
| AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR
finance.yahoo.com - August 31 at 3:40 PM |
| AMRI shareholders approve sale of company
finance.yahoo.com - August 18 at 4:01 PM |
| Albany Molecular Research, Inc. (NASDAQ:AMRI) Expected to Announce Earnings of $0.23 Per Share
www.americanbankingnews.com - August 12 at 2:26 PM |
| Albany Molecular Research, Inc. (AMRI) Expected to Announce Quarterly Sales of $171.94 Million
www.americanbankingnews.com - July 27 at 3:05 PM |
| Albany Molecular Research, Inc. (NASDAQ:AMRI) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:12 AM |
| Albany Molecular Research, Inc. (AMRI) Expected to Announce Earnings of $0.23 Per Share
www.americanbankingnews.com - July 25 at 9:20 AM |
| Albany Molecular Research, Inc. -- Moody's assigns B3 CFR to UIC Merger Sub, Inc. (dba Albany Molecular Research, Inc.)
finance.yahoo.com - July 19 at 5:02 PM |
| The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Albany Molecular Research, Inc. – AMRI
finance.yahoo.com - July 17 at 4:10 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Albany Molecular Research, Inc. (AMRI)
finance.yahoo.com - July 13 at 4:35 PM |
| SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Albany Molecular Research, Inc. - AMRI
finance.yahoo.com - July 5 at 9:00 PM |
| Analysts Anticipate Albany Molecular Research, Inc. (AMRI) Will Post Quarterly Sales of $171.94 Million
www.americanbankingnews.com - July 1 at 10:04 AM |
| AMRI chief gives a billion reasons why the company is about to be sold
www.bizjournals.com - July 1 at 1:56 AM |
| Carlyle Group takes out Albany Molecular Research for $21.75/share; +9% premarket
seekingalpha.com - June 6 at 8:34 PM |
 | GTCR and Carlyle Group are buying Albany Molecular Research for $922 million
www.businessinsider.com - June 6 at 8:34 PM |
 | Albany Molecular Research (AMRI) Agrees to Be Acquired by The Carlyle Group and GTCR for $21.75/Share
www.streetinsider.com - June 6 at 8:34 PM |
 | Exclusive: GTCR, Carlyle in talks to acquire Albany Molecular Research - sources
www.reuters.com - June 5 at 6:25 PM |
| Global Contract Research Outsourcing - Services
www.bizjournals.com - May 29 at 3:55 PM |
| Morgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
www.streetinsider.com - May 11 at 3:53 PM |
| Morgan Stanley Downgrades Albany Molecular Research Inc. (AMRI) to Equalweight
www.streetinsider.com - May 11 at 3:53 PM |
| Albany Molecular Research, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 10 at 3:43 PM |
 | Albany Molecular Research posts 1Q loss
marketbeat.com - May 9 at 8:43 AM |
| AMRI will bring work from newly awarded federal grant to Buffalo, where it will soon have 40 employees
www.bizjournals.com - May 2 at 3:36 PM |
| BRIEF-Albany Molecular Research says AMRI receives NIH contract award
www.reuters.com - May 2 at 3:36 PM |
| Denovo Biopharma Obtains Exclusive License to Liafensine from Albany Molecular Research (AMRI)
www.streetinsider.com - April 24 at 10:42 AM |
| BRIEF-Albany Molecular Research files for secondary offering of 2.2 mln shares
www.reuters.com - March 17 at 4:13 PM |
Albany Molecular Research (NASDAQ:AMRI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Albany Molecular Research (NASDAQ:AMRI) Income Statement, Balance Sheet and Cash Flow Statement
Albany Molecular Research (NASDAQ AMRI) Stock Chart for Sunday, April, 22, 2018
Loading chart…
